Market Overview

UPDATE: Goldman Sachs Downgrades DaVita to Neutral on Near-Term Momentum Slowdown

Related DVA
UPDATE: KeyBanc Capital Markets Downgrades DaVita HealthCare Partners Inc On Balanced Risk/Reward
Benzinga's Top Downgrades

Goldman Sachs downgraded DaVita (NYSE: DVA) from Buy to Neutral and maintained a $120.00 price target.

Goldman Sachs noted, "We downgrade DVA to Neutral from Buy as we think the stock is now fairly valued and as we see more upside in other areas of our coverage. While our outlook for core dialysis remains solid and we continue to see strong long-term growth potential in physician (HCP) and dialysis integrated care, we expect slower growth with less upward momentum to our/Street view over the next 12-24 months."

DaVita closed at $119.21 on Thursday.

Latest Ratings for DVA

DateFirmActionFromTo
Sep 2014KeyBancDowngradesBuyHold
Aug 2014Deutsche BankDowngradesBuyHold
Jul 2014Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Analyst Ratings

 

Related Articles (DVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters